Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Glick

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Oncology (Toronto, Ont.)|February 23, 2024
Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in OncologyAnupam Batra, Daniel Glick, Mario Valdes
Newsweek|December 27, 1993
America's nuclear secretsRussell Watson, Daniel Glick, Mark Hosenball, et al.
Clinical Lung Cancer|October 20, 2018
Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter AnalysisDoran Ksienski, Elaine S Wai, Nicole Croteau, et al.
International Journal of Radiation Oncology, Biology, Physics|April 23, 2018
Low Incidence of Esophageal Toxicity After Lung Stereotactic Body Radiation Therapy: Are Current Esophageal Dose Constraints Too Conservative?Vivian Yau, Patricia Lindsay, Lisa Le, et al.
Clinical Lung Cancer|September 25, 2017
Survival Impact of Cardiac Dose Following Lung Stereotactic Body RadiotherapyOlive Y Wong, Vivian Yau, Julie Kang, et al.
Clinical Lung Cancer|May 16, 2018
SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer-A Safety and Efficacy TrialMeredith Giuliani, Ashwathy S Mathew, Houda Bahig, et al.
Clinical Lung Cancer|October 26, 2017
Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT)Daniel Glick, Stephen Lyen, Sonja Kandel, et al.
BMC Cancer|October 6, 2018
Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5Robert Olson, Mitchell Liu, Alanah Bergman, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Oncology (Toronto, Ont.)|February 23, 2024
Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in OncologyAnupam Batra, Daniel Glick, Mario Valdes
Newsweek|December 27, 1993
America's nuclear secretsRussell Watson, Daniel Glick, Mark Hosenball, et al.
Clinical Lung Cancer|October 20, 2018
Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter AnalysisDoran Ksienski, Elaine S Wai, Nicole Croteau, et al.
International Journal of Radiation Oncology, Biology, Physics|April 23, 2018
Low Incidence of Esophageal Toxicity After Lung Stereotactic Body Radiation Therapy: Are Current Esophageal Dose Constraints Too Conservative?Vivian Yau, Patricia Lindsay, Lisa Le, et al.
Clinical Lung Cancer|September 25, 2017
Survival Impact of Cardiac Dose Following Lung Stereotactic Body RadiotherapyOlive Y Wong, Vivian Yau, Julie Kang, et al.
Clinical Lung Cancer|May 16, 2018
SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer-A Safety and Efficacy TrialMeredith Giuliani, Ashwathy S Mathew, Houda Bahig, et al.
Clinical Lung Cancer|October 26, 2017
Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT)Daniel Glick, Stephen Lyen, Sonja Kandel, et al.
BMC Cancer|October 6, 2018
Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5Robert Olson, Mitchell Liu, Alanah Bergman, et al.
Pageof 1